力扑素治疗胃癌术后腹腔转移伴恶性肠梗阻1例临床分析  

The Treatment with Paclitaxel Liposome for a Patient with Malignant Bowel Obstruction and Hypokalemia Caused by Postoperative Peritoneal Metastasis of Gastric Cancer

作　　者：陈思佳 陶家龙[1] 赵敏艳[1] 王辉[1] 张玉松[1] CHEN Si-jia;TAO Jia-long;ZHAO Min-yan;WANG Hui;ZHANG Yu-song(Department of Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215004, China)

机构地区：[1]苏州大学附属第二医院肿瘤科,江苏苏州215004

出　　处：《中国血液流变学杂志》2017年第2期180-183,共4页Chinese Journal of Hemorheology

摘　　要：目的 观察脂质体紫杉醇（力扑素）治疗胃癌腹腔转移伴恶性肠梗阻患者的疗效和安全性,为力扑素在临床上治疗类似患者提供经验.方法 通过近期在临床中收治的1例胃癌术后腹腔转移伴恶性肠梗阻和顽固性低钾血症患者,观察予以力扑素单药化疗后患者肠梗阻及低血钾的缓解情况和不良反应.结果 该例患者经力扑素治疗后肠梗阻及低血钾均得到有效缓解,不良反应较轻,患者可以耐受.结论 胃癌腹腔转移伴恶性肠梗阻及低钾血症治疗难度较大,预后差,力扑素治疗这类患者安全有效,是临床上类似患者的首选治疗药物之一.Objective Toevaluate the efficacy and safety of liposome-paclitaxel in the treatment of postoperative peritoneal metastasis of gastric cancer with malignant bowel obstruction, and to provide experience for using liposome-paclitaxel to treat similar patients. Methods We recently treated a patient with malignant bowel obstruction and refractory hypokalemia caused by postoperative peritoneal metastasis of gastric cancer, to explore response and efficacy of monochemotherapywith liposome-paclitaxel. Results In this case, malignant bowel obstruction and hypokalemia were remission. Adverse effect of liposome-paclitaxel was mild and well tolerated. Conclusion Peritoneal metastasis of gastric cancer with malignant bowel obstruction and refractory hypokalemia is difficult to manage. The prognosis is poor. Liposome-paclitaxel is effective and safe for such patients, and is one of the primary drugs in the treatment of similar patients.

关 键 词：脂质体紫杉醇 胃癌 恶性肠梗阻 低钾血症 

分 类 号：R735.2[医药卫生—肿瘤]